These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35409790)

  • 21. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine for opiate dependence: clinic based therapy in Israel.
    Goren L; Carmel Z; Marchevsky S
    Isr J Psychiatry Relat Sci; 2014; 51(4):281-4. PubMed ID: 25841225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
    Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
    Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
    Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Edwards RR; Samet JH
    Drug Alcohol Depend; 2016 Sep; 166():26-31. PubMed ID: 27422763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
    Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
    Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine.
    Stein MD; Herman DS; Moitra E; Hecht J; Lopez R; Anderson BJ; Brown RA
    Drug Alcohol Depend; 2015 Feb; 147():243-50. PubMed ID: 25510307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methadone and buprenorphine for the management of opioid dependence in pregnancy.
    Jones HE; Finnegan LP; Kaltenbach K
    Drugs; 2012 Apr; 72(6):747-57. PubMed ID: 22512363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
    Wakeman SE; McGovern S; Kehoe L; Kane MT; Powell EA; Casey SK; Yacorps GM; Irvin JR; Rodriguez W; Regan S
    J Subst Abuse Treat; 2022 Oct; 141():108848. PubMed ID: 35926256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.
    Unger A; Jagsch R; Jones H; Arria A; Leitich H; Rohrmeister K; Aschauer C; Winklbaur B; Bäwert A; Fischer G
    Addiction; 2011 Jul; 106(7):1355-62. PubMed ID: 21438938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
    Wei LC; Chan HY
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):590-598. PubMed ID: 34402338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
    Ahmadi J; Jahromi MS; Ehsaei Z
    Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing Inequities in Opioid Use Disorder Treatment Trials.
    Schiff DM; Nidey N; Tiako MJN
    JAMA Netw Open; 2024 Oct; 7(10):e2436582. PubMed ID: 39365588
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.